DGAP-News

Mainz Biomed Appoints Steve Quinn as VP Business Development

DGAP-News: Mainz BioMed N.V. / Key word(s): Personnel Mainz Biomed Appoints Steve Quinn as VP Business Development 27.01.2022 / 09:01 The issuer is solely responsible for the content of this announcement. Highly experienced diagnostics business development executive appointed to lead growth initiatives across international markets and drive international sales of ColoAlert at-home screening test for Colorectal Cancer

BERKELEY, US - MAINZ, Germany - JANUARY 27, 2022 - Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Steve Quinn as Vice President of Business Development.

"We're very excited to welcome Steve to the team. He comes to us with strong commercial experience in the field of both molecular genetics and diagnostics," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "The impressive global network he has built during his notable business development career will be highly valuable as we look to expand the markets for our ColoAlert diagnostic test across Europe and into the Middle East and Asia and later across the United States pending FDA approval."

Steve is a former medical technologist having spent several years working for the UK's NHS. His in-depth commercial experience spans both medical devices and molecular genetics and he has held a number of senior executive positions with international healthcare organizations including, OneOme, Progenity and Abbott Diagnostics.

In these previous roles, he has successfully led the introduction of new technologies to international markets and developed international business through distributor partnerships including private and public laboratories, pharmacy chains, private hospitals, public hospitals, and country-specific distribution partners. In his role as VP Business Development, Steve will provide overall leadership and strategic direction for all new Company business development initiatives across international markets.